Merck & Co Inc (NYSE:MRK) and Eisai Co Ltd (OTC:ESALY) (OTC:ESALF) announced that the Phase 3 LEAP-001 trial of Keytruda (pembrolizumab) plus Lenvima (lenvatinib) did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) as first-line treatment for patients with advanced or recurrent endometrial carcinoma.

In September, the Phase 3 LEAP-006 trial of Keytuda plus Lenvima in combination with Alimta (pemetrexed) and platinum-containing chemotherapy did not meet its dual primary endpoints of OS and (PFS) versus Keytruda with pemetrexed and platinum-containing chemotherapy in certain types of lung cancer.

In April this year, after disappointing data, Merck and Eisai discontinued the Phase 3 LEAP-003 trial of Keytruda plus Lenvima for the first-line treatment of adults with unresectable or metastatic melanoma.

In May, OS analysis of the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial for the first-line treatment of advanced renal cell carcinoma showed that after four years of follow-up, Keytruda plus Lenvima maintained a clinically meaningful OS benefit versus sunitinib, reducing the risk of death by 21%.